Yuelong Wang

ORCID: 0000-0001-6457-0481
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Pituitary Gland Disorders and Treatments
  • Glioma Diagnosis and Treatment
  • Advanced ceramic materials synthesis
  • Cancer, Hypoxia, and Metabolism
  • Drilling and Well Engineering
  • Electrospun Nanofibers in Biomedical Applications
  • Target Tracking and Data Fusion in Sensor Networks
  • Nanoparticle-Based Drug Delivery
  • Nanoplatforms for cancer theranostics
  • CAR-T cell therapy research
  • Bone Tissue Engineering Materials
  • biodegradable polymer synthesis and properties
  • Intracerebral and Subarachnoid Hemorrhage Research
  • Industrial Technology and Control Systems
  • Machine Learning in Bioinformatics
  • MXene and MAX Phase Materials
  • Immune cells in cancer
  • Energy Load and Power Forecasting
  • Spinal Cord Injury Research
  • Nerve injury and regeneration
  • Smart Grid and Power Systems
  • Brain Metastases and Treatment
  • Neuroinflammation and Neurodegeneration Mechanisms
  • Oil and Gas Production Techniques
  • Immune Cell Function and Interaction

Changchun University of Chinese Medicine
2022-2025

Sichuan University
2015-2024

West China Hospital of Sichuan University
2014-2024

Xi'an Shiyou University
2010-2024

Jiangxi University of Finance and Economics
2022-2024

Guilin University of Technology
2024

Xinjiang University
2023-2024

Inner Mongolia Electric Power (China)
2023-2024

Changchun University of Technology
2023

Guangdong University of Technology
2022-2023

Glioblastoma (GBM) remains one of the most malignant primary tumors in adults, with a 5-year survival rate less than 10% because lacking effective treatment. Here, we aimed to explore whether B7-H3 could serve as novel therapeutic target for GBM chimeric antigen receptor (CAR) T cell therapy. In this study, CAR targeting was constructed and transduced into cells by lentivirus. Antitumor effects B7-H3-specific CAR-T were assessed lines both vitro vivo. Our results indicated that positively...

10.1016/j.omto.2019.07.002 article EN cc-by-nc-nd Molecular Therapy — Oncolytics 2019-07-23

Asthma is a chronic inflammatory disease of the airways that seriously endangers human health. Belamcanda chinensis (BC), traditional Chinese medicine, has been used to counteract asthma as it shown possess anti-inflammatory and regulatory immunity properties.The study aimed investigate mechanisms action BC in treatment asthma; "dose-effect weighted coefficient" network pharmacology method was established predict potential active compounds.Information on components content obtained by...

10.2174/0113862073254607231107074015 article EN Combinatorial Chemistry & High Throughput Screening 2025-01-01

GBM (glioblastoma multiforme) is the most common and aggressive brain tumor with no curative options available. Therefore, it imperative to develop novel potent therapeutic drugs for treatment. Here, we show that regorafenib, an oral multi-kinase inhibitor, exhibits superior efficacy over temozolomide, first-line chemotherapeutic agent treatment both in vitro vivo. Mechanistically, regorafenib directly stabilizes PSAT1 (phosphoserine aminotransferase 1), a critical enzyme serine synthesis,...

10.1080/15548627.2019.1598752 article EN Autophagy 2019-04-09

Recently, B7-H3 was frequently reported to be overexpressed in various cancer types and has been suggested a promising target for immunotherapy. In the present study, we analyzed mRNA expression of The Cancer Genome Atlas (TCGA) database validated its across multiple types. We then generated novel B7-H3-targeted chimeric antigen receptor (CAR) tested antitumor activity both

10.1016/j.omto.2020.03.019 article EN cc-by-nc-nd Molecular Therapy — Oncolytics 2020-04-07

Despite improvements in microscopically neurosurgical techniques made recent years, the prognosis of adamantinomatous craniopharyngioma (ACP) is still unsatisfactory. Little known about cellular atlas and biological features ACP. Here, we carried out integrative analysis 44,038 single-cell transcriptome profiles to characterize landscape intratumoral heterogeneity tumor microenvironment (TME) Four major neoplastic cell states with distinctive expression signatures were defined, which further...

10.1126/sciadv.adc8933 article EN cc-by-nc Science Advances 2023-04-12

Wound healing, a complex process involving several important biomolecules and pathways, requires efficient dressings to enhance the therapy effects.

10.1039/c7py00038c article EN Polymer Chemistry 2017-01-01

A novel method of ultraviolet vapour generation (UVG) coupled with atomic fluorescence spectrometry (AFS) was developed for the determination ultratrace inorganic arsenic (iAs) in surface water.

10.1039/c5an02489g article EN The Analyst 2016-01-01

Glioblastoma is the most common brain cancer in adults. It represents one of top ten malignant tumors with an average survival time nine months despite treatments surgery, radiotherapy and chemotherapy. Curcumin a phytochemical turmeric isolated from root Curcuma longa plant. Accumulating evidence have proved that curcumin targets numerous signaling pathways. The E3 ubiquitin ligase NEDD4, neural precursor cell expressed developmentally downregulated protein 4, frequently overexpressed...

10.3892/ijo.2017.4037 article EN cc-by-nc-nd International Journal of Oncology 2017-06-08

Abstract Objective We conducted a first‐in‐human study to evaluate the bioactivity and safety of B7‐H3‐targeted chimeric antigen receptor (CAR) autologous T cells for treating recurrent anaplastic meningioma. Methods Tumor tissues from patient with meningioma were evaluated B7‐H3 expression. CAR‐T delivered into intracranial tumor resection cavity using an Ommaya device at maximum dose 1.5 × 10 7 cells. Magnetic resonance imaging (MRI) screening multiple serum indexes regularly monitored....

10.1002/cti2.1137 article EN cc-by-nc-nd Clinical & Translational Immunology 2020-01-01

Chemotherapy works against tumors by inducing cell apoptosis; however, evasion of apoptosis is recognized to result in resistance anticancer therapy. Ferroptosis an iron-dependent death pathway that differs from morphological, biochemical, and genetic levels. Combined ferroptosis may shed light on strategies for cancer treatment. Therefore, we have designed a nanoparticle (NP) can simultaneously cause tumor ferroptosis. This NP composed epigallocatechin gallate (EGCG) Fe3+ through simple...

10.1021/acsabm.0c00225 article EN ACS Applied Bio Materials 2020-06-02

The therapeutic use of bispecific T-cell engaging (BiTE) antibodies has shown great potential for treating malignancies. BiTE can simultaneously engage CD3ε on T cells and tumor antigen cancer cells, thus exerting an effective antitumor effect. Nevertheless, challenges in production, manufacturing, short serum half-life have dampened some the promise impeded pace BiTE-based therapeutics to combat diseases. Nowadays, vitro-transcribed mRNA achieved programmed which is more flexible...

10.1002/advs.202205532 article EN cc-by Advanced Science 2022-11-20

Epithelial–mesenchymal transition (EMT) mediated by fluid shear stress (FSS) in the tumor microenvironment plays an important role driving metastasis of malignant tumor. As a mechanotransducer, Yes‐associated protein (YAP) is known to translocate into nucleus initiate transcription genes involved cell proliferation upon extracellular biophysical stimuli. Here, we showed that FSS facilitated cytoskeleton rearrangement hepatocellular carcinoma cells, which led release YAP from its binding...

10.1002/1878-0261.13061 article EN cc-by Molecular Oncology 2021-07-14

Craniopharyngioma (CP) is a common refractory tumor of the central nervous system. However, little known about expression and clinical significance B7 family ligands/receptors in CP patients. Thus, we conducted present study to address this issue cohort 132 cases.We mapped quantified molecules programmed cell death ligand 1 (PD-L1), B7-H3, B7-H4 V-domain Ig-containing suppressor T activation (VISTA) 89 adamantinomatous-type 43 papillary-type samples using immunohistochemistry...

10.1136/jitc-2019-000406 article EN cc-by-nc Journal for ImmunoTherapy of Cancer 2020-09-01
Coming Soon ...